Cancer Research UK and Abcam Launch Custom Partnership to Accelerate Cancer Research
Retrieved on:
Tuesday, July 7, 2020
Under the terms of the partnership, Abcam will develop custom protein-based reagents to targets identified by Cancer Research UK-funded researchers.
Key Points:
- Under the terms of the partnership, Abcam will develop custom protein-based reagents to targets identified by Cancer Research UK-funded researchers.
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's commercial activity operates through Cancer Research Technology Ltd., a wholly owned subsidiary of Cancer Research UK.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.